Amgen Inc.

AMGN · NasdaqGS · Stock · Healthcare

$425.53

+3.07% today

Delayed price, 2026-10-14 16:29 UTC

What Amgen does

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Key facts

Sector

Healthcare

Industry

Drug Manufacturers - General

Market cap

$230.06B

P/E (ttm)

26.4

Forward P/E

17.4

Dividend yield

2.44%

Beta

0.41

Profit margin

23.0%

Employees

31,500

Headquarters

Thousand Oaks, CA, United States

Exchange

NasdaqGS

Website

www.amgen.com

Performance

1 Month

+10.3%

3 Months

+16.2%

6 Months

+19.8%

1 Year

+42.4%

5 Years

+114.0%

$288.0052-week range$447.03

Biggest setback — last 12 months

-15.9%

23 Feb 2026 → 11 May 2026

Fell from $388.16 to $326.31 — its sharpest sustained decline this year.

Biggest run-up — last 12 months

+50.6%

20 Oct 2025 → 17 Aug 2026

Ran from $291.76 to $439.33 — its strongest sustained advance this year.

Price outlook — trend & volatility model

● Trend: Above long-term trend

Price sits above its 200-day average, but the shorter-term averages are not cleanly aligned above/below it.

Horizon	Bear case (−1σ)	Base case	Bull case (+1σ)
1 Month	$388.88 (-8.6%)	$425.53	$465.64 (+9.4%)
3 Months	$364.06 (-14.4%)	$425.53	$497.38 (+16.9%)
6 Months	$341.28 (-19.8%)	$425.53	$530.58 (+24.7%)
12 Months	$311.47 (-26.8%)	$425.53	$581.36 (+36.6%)

Statistical, not machine-learning: a random-walk (no assumed drift) volatility model built from this ticker's own realized price history, plus a purely descriptive moving-average trend read. Illustrative only — not a price target and not financial advice. The bear and bull cases sit one standard deviation (1σ) below and above today's price, a range that covers about 68% of the outcomes the model treats as plausible, not a 68% chance of either case. Annualized volatility used: 31.2%, blended from this ticker's own 3-month and 1-year realized price history. Base case is deliberately flat — this quantifies a possible range, not a directional prediction. See the full model, including wider (≈95%) bands →

Comparable companies

950160.KQ

Kolon TissueGene, Inc.

14,100.00 KRW · -0.8%

Gilead Sciences, Inc.

$152.34 · +3.0%

VRTX

Vertex Pharmaceuticals Incorporated

$495.85 · +2.2%

Recent headlines

Amgen (AMGN) Gains Attention On Aging Treatments, Is The Upside Already Priced In? — Simply Wall St.What Could Amgen (AMGN) 70% Remission Trial Result Mean For Its Pipeline? — Simply Wall St.Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy? — Insider Monkey Amgen (AMGN) Stock Could Be 40% Undervalued On KRAS Market Growth News — Simply Wall St.Amgen (AMGN) Laps the Stock Market: Here's Why — Zacks Amgen (AMGN) and Johnson & Johnson (JNJ) Catch Jim Cramer’s Eye for Different Reasons — Insider Monkey

Recent insider activity

Sold 4,504 shares at $416.43 — Khosla Rachna, SVP, Business Development · 2026-08-13

Acquired 730 shares — Busch Matthew C., VP, Finance & CAO · 2026-08-12

Acquired 85 shares — ISHRAK OMAR, Director · 2026-08-10

Acquired 103 shares — HOLLEY CHARLES M, Director · 2026-08-10

Acquired 64 shares — Drake Michael V, Director · 2026-08-10

Source: SEC Form 4 filings. An "acquired" entry with no price is typically a stock award or option exercise rather than an open-market purchase. Search all insider trades →

Learn the basics

What is a stock? Understanding risk and reward Why diversification matters

Prices and company data are delayed reference figures from public sources (Yahoo Finance, SEC EDGAR) and may be inaccurate or out of date. This page is informational only — it is not investment advice or a recommendation to buy or sell any security. Past performance does not indicate future results.